Disclaimer: This article has been developed and funded by Daiichi Sankyo ... in breast and lung cancer, two of the most common cancers and biggest killers in our society. Precision medicines ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effe ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan ... in the press release. According to the American Cancer Society, breast cancer is the most common cancer in ...

The FY2024 revenue forecast remains unchanged, despite delays in approvals for Datroway in the lung cancer field ... offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect ...